Press Release: SCYNEXIS : SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations...
Read full article »
Scynexis is a New Jersey-based biotechnology company that researches, develops, and commercializes novel anti-infective therapies for the treatment of fungal infections.
Read more